Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 685Breast Neoplasms 584Neoplasms 468Colorectal Neoplasms 298Prostatic Neoplasms 262Neoplasm Metastasis 256Melanoma 241Ovarian Neoplasms 228Recurrence 216Lung Neoplasms 203Multiple Myeloma 195Lymphoma, Non-Hodgkin 155Pancreatic Neoplasms 154Leukemia, Myeloid, Acute 141Carcinoma, Hepatocellular 141Stomach Neoplasms 137Lymphoma 131Carcinoma, Renal Cell 128Glioblastoma 118Head and Neck Neoplasms 112Squamous Cell Carcinoma of Head and Neck 111Lymphoma, Follicular 106Leukemia, Lymphocytic, Chronic, B-Cell 99Lymphoma, Large B-Cell, Diffuse 96Leukemia 96Small Cell Lung Carcinoma 95Brain Neoplasms 91Carcinoma 82Uterine Cervical Neoplasms 76Triple Negative Breast Neoplasms 72

Interventions

130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × TNBC × Clear all
NCT07376629 2026-01-29

A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC

Huabo Biopharm Co., Ltd.

Phase 2 Enrolling by invitation
60 enrolled
Breast

TNBC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡